Jeffrey W. Albers
CIK: 0001638474
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (43 total)
- Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct5K shares at avg. $104.47$522K - Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
Exercise(M)Direct5K shares at avg. $10.39$52K - Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Indirect10K shares at avg. $104.68$1.0M - Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Indirect8K shares at avg. $104.38$835K - Jun 24, 2026KYMR
Kymera Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
6.1K shares- - May 27, 2026SYRE
Spyre Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
8K shares- - Dec 8, 2025KYMR
Kymera Therapeutics, Inc.
Exercise(M)Direct5K shares at avg. $14.18$71K - Dec 8, 2025KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct2.7K shares at avg. $89.32$245K - Dec 8, 2025KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct2.3K shares at avg. $90.30$203K - Oct 13, 2025KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct5K shares at avg. $59.19$296K - Oct 13, 2025KYMR
Kymera Therapeutics, Inc.
Exercise(M)Direct5K shares at avg. $10.34$52K - Jul 17, 2025BPMC
Blueprint Medicines Corp
Disposition(D)Direct5.8K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Tender Offer(U)Direct144.8K shares- - Jun 25, 2025KYMR
Kymera Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
16K shares- - Jun 18, 2025BPMC
Blueprint Medicines Corp
Award(A)Direct3.9K shares at avg. $128.12$500K - Jun 3, 2025KYMR
Kymera Therapeutics, Inc.
Exercise(M)Direct6.3K shares at avg. $10.34$66K - Jun 3, 2025KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct6.3K shares at avg. $49.00$311K - May 29, 2025SYRE
Spyre Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
25K shares- - May 27, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct650 shares at avg. $101.93$66K - May 27, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct4.4K shares at avg. $101.02$439K - May 27, 2025BPMC
Blueprint Medicines Corp
Exercise(M)Direct5K shares at avg. $36.05$180K - Mar 12, 2025BPMC
Blueprint Medicines Corp
Exercise(M)Direct7.5K shares at avg. $36.05$270K - Mar 12, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct5.7K shares at avg. $87.62$499K - Mar 12, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct1.8K shares at avg. $88.37$159K - Mar 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct5.8K shares at avg. $88.80$512K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 7, 2026 |  SYRE Spyre Therapeutics, Inc. | Sale(S) | 5,000 | $104.47 | $522,350 | Direct |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Exercise(M) | 5,000 | $10.39 | $51,950 | Direct |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 10,000 | $104.68 | $1,046,800 | Indirect |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 8,000 | $104.38 | $835,040 | Indirect |
| Jun 24, 2026 |  KYMR Kymera Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 6,068 | - | - | Direct |
| May 27, 2026 | SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 8,026 | - | - | Direct |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | Exercise(M) | 5,000 | $14.18 | $70,900 | Direct |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 2,748 | $89.32 | $245,460 | Direct |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 2,252 | $90.30 | $203,363 | Direct |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 5,000 | $59.19 | $295,949 | Direct |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | Exercise(M) | 5,000 | $10.34 | $51,700 | Direct |
| Jul 17, 2025 |  BPMC Blueprint Medicines Corp | Disposition(D) | 5,777 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Tender Offer(U) | 144,755 | - | - | Direct |
| Jun 25, 2025 | KYMR Kymera Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 16,000 | - | - | Direct |
| Jun 18, 2025 | BPMC Blueprint Medicines Corp | Award(A) | 3,902 | $128.12 | $499,924 | Direct |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | Exercise(M) | 6,349 | $10.34 | $65,649 | Direct |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 6,349 | $49.00 | $311,101 | Direct |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| May 27, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 650 | $101.93 | $66,255 | Direct |
| May 27, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 4,350 | $101.02 | $439,437 | Direct |
| May 27, 2025 | BPMC Blueprint Medicines Corp | Exercise(M) | 5,000 | $36.05 | $180,250 | Direct |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | Exercise(M) | 7,500 | $36.05 | $270,375 | Direct |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 5,700 | $87.62 | $499,434 | Direct |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 1,800 | $88.37 | $159,066 | Direct |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 5,766 | $88.80 | $512,021 | Direct |
1-25 of 43 transactions
About Albers Jeffrey W.
Albers Jeffrey W. (SEC CIK 0001638474) files insider reports with the SEC as Director of Spyre Therapeutics, Inc. (SYRE), Director of Kymera Therapeutics, Inc. (KYMR) and Director of Blueprint Medicines Corp (BPMC).
Signal8 holds 20 ownership filings by Albers Jeffrey W., all Form 4s, filed between Sep 11, 2024 and Aug 10, 2026. Those filings report 43 transactions, from Sep 9, 2024 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Albers Jeffrey W.'s filings is in WALTHAM, MA.
Recent filings by Albers Jeffrey W.
- Aug 7, 2026: Open-market sale of SYRE shares (Form 4, code S).
- Aug 7, 2026: Option exercise of SYRE shares (Form 4, code M).
- Aug 7, 2026: Open-market sales of SYRE shares (2 lines, Form 4, code S).
- Jun 24, 2026: Grant or award of KYMR derivative securities (Form 4, code A).
- May 27, 2026: Grant or award of SYRE derivative securities (Form 4, code A).
Other insiders filing for Spyre Therapeutics, Inc. (SYRE)
- King-Jones Heidy
- Turtle Cameron, Chief Executive Officer
- Burrows Scott L, Chief Financial Officer
- Sloan Sheldon, Chief Medical Officer
- Fairmount Funds Management LLC, Director
- HENDERSON MICHAEL THOMAS, Director